The newly parturient cow secretes large quantities of immunoglobulin Gl, a relatively protease-and heat-resistant immunoglobulin, in its colostrum and milk. This study establishes the feasibility of producing protective colostral immunoglobulins by immunizing pregnant cows with cholera toxin (CT), a CT-related enterotoxin from Escherichia coli, and Vibrio cholerae outer membranes (OMs). The OMs were prepared from bacteria grown under iron-replete or iron-deficient (to simulate the in vivo environment) conditions. Immunoglobulins were purified from the colostrum of newly parturient control and immunized cows. The bovine anti-CT and anti-H-LT (CT-related heat-labile enterotoxin produced by diarrheagenic E. coli strains of human origin) antibodies were quantitated by enzyme-linked immunosorbent assays and by neutralization of toxin activity in both Y-1 adrenal cell and infant rabbit assays. The bovine anti-OM antibodies from both high-iron-grown and low-iron-grown vibrios were assessed by bacterial agglutination and by Western blot (immunoblot) analysis of polyacrylamide gel electrophoresis of high-iron-grown and low-iron-grown OMs. To test their protective effect, immunoglobulin preparations were administered orally in infant feeding formula to 6-day-old rabbits. Anti-CT and anti-OM immunoglobulins elicited statistically significant protection against diarrhea in infant rabbits challenged intraintestinally with virulent cholera vibrios.
Although marred by confounding variables, the vast majority of studies which have been conducted (3, 9, 21, 23, 25, 37) have found that breast-feeding reduced the risk of diarrheal disease morbidity and mortality in infants under 1 year of age. In light of these findings, the World Health Organization is engaged in a global effort to promote breastfeeding. Nevertheless, a substantial number of infants are, for a variety of reasons, not breast-fed. Additionally, it should be recognized that the protection passively imparted by breast-feeding may be limited by the immunological experience of individual mothers. Thus, it might be beneficial to consider that even more potent, broad-spectrum, and targeted immunity can be provided in infant feeding formulae supplemented with specific antibodies. Orally administered antibodies might also be protective in older age groups.
Although the figures vary at different times and in different places (4, 22, 29) , overall a significant proportion of the diarrheal diseases in infants and young children are caused by bacteria that elaborate enterotoxins which are immunologically, structurally, and functionally related to cholera enterotoxin (CT), such as H-LT, a heat-labile enterotoxin produced by diarrheagenic Escherichia coli strains of human origin (17) .
The newly parturient cow secretes large quantities of immunoglobulin Gl (IgGl), a relatively protease-resistant immunoglobulin, in its colostrum and milk (20, 24, 28) . We have immunized pregnant cows with CT, with H-LT, and outer membranes (OMs) prepared from Vibrio cholerae grown under iron-replete or iron-deficient (to simulate the in vivo environment) conditions (15, (31) (32) (33) . The immune response before and after parturition was followed by serum antibody measurements. Purified bovine colostral immunoglobulins containing antitoxic or antibacterial antibodies were found to protect infant rabbits from diarrhea resulting from direct intraintestinal live vibrio challenge. The results will be pertinent to future studies to define antibodies which, when administered orally, will contribute to protection against diarrheal disease in adults and, more importantly, in children.
(Portions of this work were presented in preliminary fashion at (11, 17) , which had been heated to reduce toxicity and to cause aggregation resulting in the formation of "procoligenoid" (16) of potentially increased immunogenicity. Additional cows were immunized with 10-mg doses of an analogous preparation of procholeragenoid (12) prepared from purified CT-1 (from V. cholerae 569B biotype cholerae serotype Inaba). The immunogens were emulsified 1:1 (voU vol) in Freund incomplete adjuvant (FIA) and administered intramuscularly in 2.5-ml doses in each of the four quadrants of the cows. Toxin-immunized animals were boosted 2 weeks after the initial immunization with 2-mg doses of the antigens in the same volume of FIA. Controls were inoculated with only the same volume of FIA.
After 1 year, four of the original eight cows were available for study and pregnant again. Three weeks prior to parturition, these cows were bled to determine their antibody titers and boosted with 2 mg of toxin as described above. Colos-1228 BOESMAN-FINKELSTEIN ET AL. trum was collected, and a second lot of immunoglobulin was purified from each animal. Blood was collected at delivery and every 2 weeks until the immune response diminished.
OMs were prepared from V. cholerae 3083 biotype El Tor serotype Ogawa grown either under low-iron or iron-replete conditions (15, (31) (32) (33) . The immunogens were emulsified in FIA and administered intramuscularly in 2.5-ml doses, totaling 8 mg of low-iron-grown OMs or 15 mg of highiron-grown OMs, in each of the four quadrants of additional cows. OM-immunized cows were boosted twice with 3 mg of OMs at 2-week intervals after the initial immunization, until 1 month prior to parturition. Controls were inoculated with the same volume of FIA only.
Purification of bovine colostral immunoglobulin. Colostrum/milk was collected for 1 to 4 days postdelivery. The whole colostrum was heated to 39 to 40°C to liquefy the fat. Cream was then removed by using a DeLaval model 104 centrifugal separator. Rennin (2 mg/liter; Sigma Chemical Co., St. Louis, Mo.) was added to the resultant skim milk, and the pH was lowered to about pH 6 with 1 N HCl. After 1 to 2 h at 30°C to set the casein clot, the clear yellowish whey was obtained either by filtration through plastic cheesecloth (Vitulis and Co., Frankfort, Ind.) or by centrifugation at 9,000 x g for 15 min. The immunoglobulin was precipitated from whey at 35% saturation (19.7 g/100 ml) of ammonium sulfate at 4°C overnight. The precipitated whey was then centrifuged at 9,000 x g for 15 min, and the pellets were dissolved in water, with stirring, overnight. The small amount of casein which remained in the whey did not solubilize and was removed by centrifuging the whey again at 9,000 x g for 15 min. The soluble immunoglobulin preparation was extensively dialyzed against normal saline by using a Pellicon system (Millipore Corp., Bedford, Mass.) with a 10,000-molecular-weight cassette until sulfate was no longer detectable (i.e., <3 mg/100 ml) by precipitation with 2% BaCl2 and was finally dialyzed against phosphatebuffered saline, pH 7.0. The purified antitoxic immunoglobulin preparations were standardized to 50 mg of protein per ml (26) and stored at -20°C in 500-ml aliquots. The purified anti-OM immunoglobulin preparations were dialyzed into 0.05 M NaCl prior to storage. The preparations were >90% pure by cellulose acetate electrophoresis.
Antibody assays. Antitoxin antibody levels in serum, whey, and purified immunoglobulin were determined by enzyme-linked immunosorbent assays (ELISAs) as described previously (11) , with the exception that the secondary antibody used was peroxidase-labeled sheep anti-bovine immunoglobulin (ICN Biomedicals, Inc., Cambridge, Mass.). The optical density was determined at 410/490 nm by using an MR600 microplate reader (Dynatech Laboratories, Inc., Alexandria, Va.). For comparison purposes, an ELISA unit was defined as the smallest amount of immunoglobulin giving an optical density of 0.4, a point early in the linear portion of the dose-response curve. ELISAs were sensitive (e.g., optical density of -0.2) to about 0.4 to 0.8 jig of purified immunoglobulin per well. Purified CT-2 (V. cholerae 3083 biotype eltor serotype Ogawa), which, although related, differs immunologically from CT-1 (11, 27, 36) , was included in some assays.
The ability of serum, whey, and purified immunoglobulin to neutralize toxin was determined in Y-1 adrenal cells and in infant rabbits. In the former assay (27) (13) was then recorded at 18 h. The endpoint was the smallest amount of antibody which reduced the control choleragenic score by at least 50%.
The antibody activity in the bovine anti-OM sera and immunoglobulin preparations was assessed by bacterial agglutination (2) using high-iron-grown and low-iron-grown V. cholerae 3083 and by Western blot (immunoblot) analysis (31) (32) (33) 35) of 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% polyacrylamide) of the V. cholerae 3083 OM preparations.
The component of the total anti-OM contributed by antilipopolysaccharide (anti-LPS) antibodies was estimated by the vibriocidal antibody inhibition test, as previously described (10). V. cholerae LPS was prepared from strain 3083 by the method of Westphal and Jann (38) .
Protection studies. The protective effect in the infant rabbit model of feeding both antitoxic and anti-OM immunoglobulin preparations (in infant feeding formula) against intraintestinal challenge with virulent cholera vibrios was tested as follows. Infant rabbits (6 days old) were fed 4 ml of infant feeding formula (Enfamil; Mead Johnson Nutritional Division, Evansville, Ind.) containing the immunoglobulin preparation to be tested, on the evening before challenge, the morning of challenge (about 4 h before challenge), and 2 h after challenge. Approximately 105 vibrios (strain 569B or 3083) were injected directly into the small intestine by laparotomy. The following day, a diarrheagenic score (+ 1 to +4 by degree of wetness up the abdomen; 5, moribund; 6, dead) was taken hourly. Those scores at 11 a.m. (:20 h after challenge) were used in the studies reported here, although observations were continued until all the animals had succumbed or 48 h postchallenge (whichever was earlier). Mean, standard deviation, standard error of the mean, and P values comparing groups were determined (18) .
RESULTS
The amounts of purified colostral immunoglobulin recovered per cow and their antibody titers are summarized in Table 1 . Immunoglobulin recovery ranged from 143 to 794 g per cow. As the highest concentration of immunoglobulin was obtained on day 1, the inclusion of later milkings did not substantially increase the yield of immunoglobulin in proportion to the intensity of labor involved in processing the larger volumes. For example, cow 271 secreted 14.7, 22.6, and 52 liters on days 1, 2, and 3 and 4 (combined) postpartum, respectively, and the ELISA titers of the colostral whey were 1,600, 500, and 100 for the respective samples. Colostrum was collected for 4 days in the earlier part of the study for cows 384, 269, and 271; for 3 days for cow 238; for 2 days for cows 323, 417, 376, and 388; and for 1 day for cows 351, 382, 373, 380, 352, and 312. Cows which recalved the second year (cows 384, 238, 417, and 388) were harvested on day 1 only, except cow 388 which was harvested for 2 days (no colostrum on day 1).
The time course of the immune response was followed by determining serum antibody titers during immunization and before and after parturition. required for neutralization of toxicity as evaluated in vivo in infant rabbits (Table 3) .
To test the effect of heat on the stability of bovine IgGl antibody activity, one of the anti-H-LT immunoglobulin preparations (cow 271) was diluted to 2 mg/ml in infant feeding formula and heated for 1 h at 56 or at 63°C (pasteur- ization temperature). The anti-H-LT ELISA antibody activity was stable to heating for 1 h at 56 or 63°C under these conditions (Fig. 2) . V. cholerae agglutination titers of sera and immunoglobulin preparations from cows immunized with OMs, compared with those of nonimmune controls, are summarized in Table  4 . Interestingly, many preimmune and nonimmune sera and immunoglobulin preparations had agglutinating activity against V. cholerae, which may reflect cross-reactive antibodies produced in response to contact with antigens (dietary or normal flora) with antigenic similarities to surface components of V. cholerae or as a result of the herd immunization, given 3 weeks preparturition, which contained (among other antigens) a K99-enriched E. coli bacterin preparation. Each of the immunized cows responded with fourfold or greater rises in agglutinating antibody levels. Results of vibriocidal inhibition by V. cholerae LPS (from strain 3083) showed that the vibriocidal activity of the preimmune serum from cow 380 was markedly inhibited, whereas that of immune serum and immunoglobulin was not affected by treatment with LPS (results not shown). The vibriocidal activity of sera and immunoglobulin from the other cows tested was not affected by LPS. Thus, the predominant anti-V. cholerae antibodies of the immunized preparations were not directed against LPS. The origin of the cross-reactive antibodies is not clear, but earlier studies (10, 14) have noted the presence of complement-dependent vibriocidal antibody in the serum of Americans with no known exposure to V. cholerae antigens. Figure 3 shows Western blot analyses of the spectrum of antibodies present in OM-immunized and nonimmune cows against OM components of both high-iron-grown and lowiron-grown V. cholerae 3083. Arrows (Fig. 3, lanes 2A, 3A, and 4A) indicate areas of the blot in which one or several bands were present only in the low-iron-grown OMs, probably proteins whose synthesis is induced by low-iron stress (shown to simulate in vivo conditions [15, [31] [32] [33] it is clear that more stained bands are evident in the low-iron-grown OMs (A lanes versus B lanes) .
Protection against V. cholerae 3083-induced diarrhea (live vibrio challenge) in infant rabbits by feeding bovine anti-OM immunoglobulin from strain 3083, anti-CT-1 immunoglobulin, and control immunoglobulin is shown in Fig. 4 through 6 . The oral administration of three 50-mg doses of bovine anti-OM (both high-iron-grown and low-iron-grown) immunoglobulin (Fig. 4, bars 3 and 5) resulted in statistically significant protection (P <0.001) against V. cholerae 3083-induced diarrhea 20 h following challenge and 18 h after the last feed. A lower-dose regimen of anti-low-iron-grown-OM immune immunoglobulin (three 10-mg doses) was also protective (bar 4). Control immunoglobulin (cow 351) (bar 2) resulted in protection (P < 0.1) compared with placebo-fed rabbits (bar 1); this effect was markedly less than that seen in animals fed immune immunoglobulin. Protection was also achieved by feeding three 50-mg doses of bovine anti-OM immunoglobulin (cow 380, upper bars) against challenge with 105 live virulent vibrios of the heterologous strain V. cholerae 569B (Fig. 5) . Lower bars represent three 50-mg feeds of control immunoglobulin (cow 351). Figure 6 shows that orally administered bovine anti-CT-1 immunoglobulin (pool of immunoglobulin from cows 376 and 388) was significantly more protective than control immunoglobulin (cow 351) against live vibrio challenge with both homologous (strain 569B) and heterologous (strain 3083) V. cholerae (P < 0.005 and P < 0.001, respectively).
It should be mentioned that the protective effects observed were primarily manifested as a delay in the onset of diarrheal disease. Although some passively immunized animals remained symptom-free during the entire 48-h observation period, many did eventually succumb or express symptoms (later than the controls). We attribute these breakthroughs to the fact that feeding of antibody was not continuous after challenge. accepted that breast-fed babies fare better than their formula-fed counterparts, although, as mentioned above, almost all of the supporting studies have inherent methodological problems. Nevertheless, the abundance of evidence is convincing in itself, even though the mechanisms are not clearly understood. The protective effects may be due in part to avoidance of environmental contamination (e.g., infant feeding formula may be prepared with polluted water in dirty containers), but to a more significant degree, they probably depend on protective elements in breast milk including, especially, preformed maternal secretory IgA. The protective activity of maternal antibody would, of course, be limited by the immunological background of the mother.
The thrust of the present work is that it should be possible to complement or supplement the protection afforded by breast-feeding (or provide protection to infants who are not breast-fed) by using preformed antibody produced in another species, most notably the cow, which has been reported to secrete large amounts of a relatively protease-resistant immunoglobulin in colostrum and milk (24, 28) More recently, Brf.ssow et al. (6) and Hilpert et al. (20) treated infants with acute gastroenteritis with another MIC preparation containing rotavirus antibody, at a dose of 2 g/kg (body weight) per day for 5 days. Three preparations, differing quantitatively in antibody level, were used; none was therapeutic, and only the highest-titer preparation reduced the period of excretion of rotavirus.
While the present work was in progress, and most significantly, adult American volunteers fed 9 g of MIC from cows immunized with a multivalent E. coli preparation were found to be protected against challenge with an enterotoxigenic E. coli (34) . Minimal protective doses of MIC were not defined, nor were the essential antibody (or antibodies) (i.e., antisomatic, antimembrane, antiadhesin, antiflagellar, anti-H-LT, or other). At this level, and again according to our results, a single cow would also provide about 100 days of prophylaxis. Preparations of higher specific activity would go further.
In experimental animal studies, McLead and Gregory (28) found that bovine colostral anti-CT immunoglobulin neutralized CT and could be detected in the cecal contents of rabbits fed anti-CT whey. Live cholera vibrio challenges were not attempted. More recently, Yoshiyama and Brown (39) reported that milk from rabbits immunized with live V. cholerae protected rats against V. cholerae challenge in intestinal loops in situ. Adsorption studies indicated that antitoxic antibodies were the only protective components of the immunized milk. It should be noted that Glass et al. (19) (34) , it may be possible to use whole milk as a source of protective antibody, and it is likewise conceivable that a cow or a herd of cows could be immunized with multiple antigens.
